profit from every $100 of sales.
$0$100
Ocular Therapeutix
$6.28-5.71% today
-45.3% in 1 year
1-year low $6.281-year high $16.11
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Ocular Therapeutix sold, what it kept, and what it did with the cash.
Sales went from $51.5 million in 2022 to $52.0 million in 2025, with -$266 million of profit last year.
SalesProfit
Ocular Therapeutix vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ocular Therapeutix | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Ocular Therapeutix's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 51 | 58 | 64 | 52 | |
| 47 | 53 | 58 | 45 | |
| -79 | -82 | -172 | -270 | |
| -62 | -66 | -176 | -250 | |
| -71 | -81 | -194 | -266 | |
| -0.97 | -1.02 | -1.22 | -1.42 | |
| 91.2% | 91.0% | 91.2% | 87.3% | |
| -152.7% | -141.0% | -269.6% | -519.8% | |
| -138.0% | -138.1% | -303.7% | -511.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 149 | 252 | 458 | 808 |
| Cash | 102 | 196 | 392 | 737 |
| Total debt | 64 | 83 | 76 | 77 |
| Total liabilities | 114 | 161 | 143 | 154 |
| 35 | 91 | 315 | 654 | |
| 83 | 86 | 158 | 187 | |
| -50.7% | -31.4% | -36.3% | -27.5% | |
| -200.8% | -88.6% | -61.4% | -40.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -60 | -70 | -135 | -205 | |
| 4 | 6 | 1 | 12 | |
| -63 | -76 | -136 | -217 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 17 | 18 | 33 | 43 |
Valuation
- –
- –
- –
- 3.5×
- 26.6×
- –
- –
- -15.7%
- -19.2%
- 0.0%
Profitability
- 87.3%
- -519.8%
- -511.9%
- -541.4%
- -43.5%
- -41.5%
- -64.6%
- -39.7%
- -43.7%
- 423.6%
Growth
- +0.3%
- –
- −59.5%
- –
- +25.1%
Financial health
- -2.6×
- 0.14
- 10.8%
- -25.8×
- 14.81
- 14.73
- 0.07
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 952
Bottom 16%of 870
Bottom 6%of 985
What analysts expect
- Average price target
- $25.50
- Range
- $21.00 – $30.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.41 | -0.32 | −28.1% |
| Feb 5, 2026 | -0.29 | -0.33 | +12.1% |
| Nov 4, 2025 | -0.37 | -0.39 | +5.1% |
| Aug 5, 2025 | -0.39 | -0.35 | −11.4% |
| May 5, 2025 | -0.37 | -0.29 | −27.6% |
| Mar 3, 2025 | -0.29 | -0.24 | −20.8% |
| Nov 14, 2024 | -0.26 | -0.23 | −13.0% |
| Aug 7, 2024 | -0.24 | -0.22 | −9.1% |
News
Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028Seeking Alpha · Nov 9, 2026Ocular gains on EyePoint phase 3 wet AMD missSeeking Alpha · Aug 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
36No pass
Benjamin Graham
41No pass
Philip Fisher
45No pass
Peter Lynch
41No pass
Joel Greenblatt
2No pass
Charlie Munger
54No pass
Terry Smith
50No pass
Questions about Ocular Therapeutix
Is Ocular Therapeutix a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ocular Therapeutix AI analysis
What does Ocular Therapeutix do?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. It is in Biotechnology.
Does Ocular Therapeutix pay a dividend?
No. Ocular Therapeutix does not pay a dividend at the moment.
Is Ocular Therapeutix stock halal?
No. Ocular Therapeutix does not pass our halal screen: its cash and confirmed interest-bearing investments are 53% of its market value, at or above the 33% limit. How we check
How has Ocular Therapeutix stock done over the past year?
Down 45.3% over the past twelve months, to $6.28. It traded between $6.28 and $16.11 and is 61.0% below its high.
Who are Ocular Therapeutix's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Ocular Therapeutix's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.